Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HR+/HER2-breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT06311383
What this trial is testing

A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 2,610
Testing effectiveness (Phase 2)UnknownNCT05411380
What this trial is testing

Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.

Who this might be right for
Breast Cancer
wang shusen 73
Large-scale testing (Phase 3)Ended earlyNCT01633060
What this trial is testing

A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 432
Early research (Phase 1)Temporarily pausedNCT03970382
What this trial is testing

Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors

Who this might be right for
Solid Tumor
PACT Pharma, Inc. 21
Large-scale testing (Phase 3)Active Not RecruitingNCT02513394
What this trial is testing

PALbociclib CoLlaborative Adjuvant Study

Who this might be right for
Breast Cancer
Alliance Foundation Trials, LLC. 5,796
Not applicableStudy completedNCT05478590
What this trial is testing

Describe Treatment Patterns of Advanced Breast Cancer in Poland in the Real-world Data Setting

Who this might be right for
Breast Neoplasms
Pfizer 440
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06254066
What this trial is testing

Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer

Who this might be right for
Female Breast Cancer PatientsHistopathologically Confirmed Advanced HR +/HER2-invasive Breast CancerHRD Positive Advanced Breast Cancer
Zhejiang Cancer Hospital 40
Early research (Phase 1)Active Not RecruitingNCT05266105
What this trial is testing

Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients

Who this might be right for
Breast Cancer
Olema Pharmaceuticals, Inc. 60
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06849947
What this trial is testing

Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer

Who this might be right for
Breast Cancer Metastatic
Yeon Hee Park 272
Large-scale testing (Phase 3)UnknownNCT04337658
What this trial is testing

Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine 493
Testing effectiveness (Phase 2)Looking for participantsNCT05983107
What this trial is testing

Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer

Who this might be right for
HR+/HER2- Advanced Breast CancerTargeted Therapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 102
Large-scale testing (Phase 3)Looking for participantsNCT05851014
What this trial is testing

GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Who this might be right for
Breast Cancer
Genor Biopharma Co., Ltd. 350
Testing effectiveness (Phase 2)Looking for participantsNCT07368998
What this trial is testing

To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 80
Early research (Phase 1)Looking for participantsNCT06139107
What this trial is testing

RADIANT: Pre-op Radiation With Abemaciclib and Letrozole

Who this might be right for
Breast Cancer
Mridula George, MD 15
Post-approval studies (Phase 4)Study completedNCT02248571
What this trial is testing

Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab

Who this might be right for
Breast Cancer RecurrentHER2/Neu-negative Carcinoma of BreastHormone Receptor Positive Malignant Neoplasm of Breast
iOMEDICO AG 85
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07292207
What this trial is testing

Abemaciclib for Molecular Residual Disease Detected by Circulating Tumor DNA in HR+/HER2- Early Breast Cancer

Who this might be right for
ctDNA MonitoringBreast Cancer
Nagoya City University 30
Testing effectiveness (Phase 2)Study completedNCT02411344
What this trial is testing

Preoperative Study With Trastuzumab, Pertuzumab and Letrozole in Breast Cancer Patients Sensitive to Hormonal Therapy

Who this might be right for
Endocrine Sensitive HER2+/HR+ Breast Cancer
Istituto Oncologico Veneto IRCCS 64
Not applicableEnded earlyNCT04436120
What this trial is testing

Treatment Resistance Following Anti-cancer Therapies

Who this might be right for
Disease Progression
Pfizer 38
Post-approval studies (Phase 4)Not Yet RecruitingNCT07162259
What this trial is testing

Cohort Study on Sequential ADC Therapy in HR-positive/HER2-negative Advanced Breast Cancer

Who this might be right for
Breast Neoplasms
Yan Xue 40
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07795424
What this trial is testing

Culmerciclib Combined With Letrozole and Dual HER2 Blockade as Neoadjuvant Therapy for HR+/HER2+ Breast Cancer

Who this might be right for
Breast CancerHR Positive, HER2 Positive Breast Cancer
Shengjing Hospital 33
Next Page